Schizophrenia Research
Volume 115, Issue 2 , Pages 136-140 , December 2009

Acetyl-coenzyme A carboxylase α gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels

  • Francisco J. Diaz

      Affiliations

    • Department of Biostatistics, Kansas University Medical School, Kansas City, Kansas, United States
    • ,
  • Alexander Meary

      Affiliations

    • INSERM, Unité 841; IMRB, Department of Genetics, Psychiatry Genetic, Créteil, F-94000, France
    • Psychological Medicine, Institute of Psychiatry – King's College, London, United Kingdom
    • ,
  • Maria J. Arranz

      Affiliations

    • Psychological Medicine, Institute of Psychiatry – King's College, London, United Kingdom
    • ,
  • Gualberto Ruaño

      Affiliations

    • Genomas, Inc., Hartford, Connecticut, United States
    • ,
  • Andreas Windemuth

      Affiliations

    • Genomas, Inc., Hartford, Connecticut, United States
    • ,
  • Jose de Leon

      Affiliations

    • University of Kentucky Mental Health Research Center at Eastern State Hospital, United States
    • University of Kentucky Colleges of Medicine and Pharmacy, Lexington, Kentucky, United States
    • Department of Psychiatry and Institute of Neurosciences, University of Granada, Granada, Spain
    • Corresponding Author InformationCorresponding author. Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington KY 40508, United States. Tel.: +1 859 246 7563; fax: +1 859 246 7019.

Received 1 June 2009 ,Revised 24 September 2009 ,Accepted 29 September 2009.

References 

  1. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of the last decade of research. Mol. Psychiatry. 2007;12:707–747
  2. Chen JL, Spinowitz N, Karwa M. Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. Pharmacotherapy. 2003;23:940–944
  3. de Leon J. Beyond the “hype” on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, and co-morbid substance use (editorial). J. Clin. Psychopharmacol. 2008;28:125–131
  4. de Leon J, Diaz FJ. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr. Res. 2007;96:185–197
  5. de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 2007;92:95–102
  6. de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr. Res. 2008;98:40–46
  7. Harwood JH. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Exp. Opin. Ther. Targets. 2005;9:267–281
  8. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006;29:170
  9. Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report (letter). J. Clin. Psychiatry. 2006;67:1473–1474
  10. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotic-induced weight gain and diabetes mellitus. Drug Metab. Pharmacokinet. 2005;20:368–378
  11. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004;70:1–17
  12. Popp J, Leucht S, Heres S, Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J. 2009;9:71–77
  13. Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry. 2007;12:474–482
  14. Woodward M. Epidemiology: Study Design and Data Analysis. Second Edition. Boca Raton, FL: Chapman & Hall/CRC; 2005;

PII: S0920-9964(09)00482-4

doi: 10.1016/j.schres.2009.09.038

Schizophrenia Research
Volume 115, Issue 2 , Pages 136-140 , December 2009

Article Tools